Luseogliflozin (TS-071) is a potent, selective, orally acitve SGLT2 inhibitor with IC50 of 2.26 nM, 1650-fold selectivity over SGLT1.
Luseogliflozin (TS-071) exhibits a blood glucose lowering effect, excellent urinary glucose excretion properties, and promising PK profiles in vivo.
Luseogliflozin (TS-071) increases urinary glucose excretion in Zucker fatty rats and beagle dogs at doses of 0.3 and 0.03 mg/kg respectively.
Luseogliflozin (TS-071) improves glucose tolerance without stimulating insulin secretion and reduces hyperglycaemia in STZ-induced diabetic rats.
